ロード中...
Agonist-Biased Signaling at the sst2A Receptor: The Multi-Somatostatin Analogs KE108 and SOM230 Activate and Antagonize Distinct Signaling Pathways
Somatostatin analogs that activate the somatostatin subtype 2A (sst2A) receptor are used to treat neuroendocrine cancers because they inhibit tumor secretion and growth. Recently, new analogs capable of activating multiple somatostatin receptor subtypes have been developed to increase tumor responsi...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
The Endocrine Society
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2802896/ https://ncbi.nlm.nih.gov/pubmed/19910453 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/me.2009-0321 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|